In Reply Ms Maruyama and colleagues question the conclusions of the CATCH trial of tinzaparin vs warfarin for the treatment of cancer-associated venous thromboembolism and raise concerns with the reporting of serious adverse events and mortality. We note that the CATCH trial was the largest study of treatment of acute venous thromboembolism in patients with active malignancy ever conducted and included a diverse study population, thereby increasing its generalizability and validity in the real-world setting. All safety and efficacy analyses were conducted with intention to treat, capturing all 900 randomized patients.
Khorana AA, Lee AYY, For the CATCH Steering Committee. Tinzaparin vs Warfarin for Acute Venous Thromboembolism—Reply. JAMA. 2016;315(2):200-201. doi:10.1001/jama.2015.15070